- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
There are only two studies in which the pharmacokinetics of levosimendan in children have been described. The study by Turanlahti et al. (single administration of 12 µg/kg in children aged 3 months – 7 yrs, n = 13) concludes that the pharmacokinetic profiles of levosimendan in adults and in children are comparable. The following values have been found:
| 3-6 months (n=5) | 6 months to 7 years (n=7) | |
|---|---|---|
| Cmax (ng/ml) | 56.9 | 59.4 |
| Cl (ml/min/kg) | 3.8 | 3.6 |
| Vd in the steady state (l/kg) | 0.43 | 0.35 |
| t½ (hours) | 2.3 | 1.6 |
The pharmacokinetics of the active metabolite were not investigated in the studies.
The study by Pellicer et al. states a Cmax for neonates averaging 16.5 ng/ml, a Tmax averaging 48 hours and a Cl/F averaging 0.67 l/h/kg.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| In acute heart failure if the standard therapy is not sufficiently effective |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No data is known about dosage adjustments for renal function disorders. In adults, an improvement in the renal function was seen on the one hand, but on the other caution is needed because of a possibly elevated exposure to active metabolites.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
The ECG, blood pressure, heart rate, cardiac output, filling pressure and urine production should be monitored during administration and for at least 3 days after discontinuing or in the case of hepatic or renal function disorders for at least 5 days or until the patient is stable. Any low serum potassium concentration should be corrected before administration and the potassium level should be monitored during administration. Severe hypovolaemia, ventricular tachycardia and paroxysmal tachycardia that is not the result of reperfusion or life-threatening arrhythmia should be corrected before administration.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Adrenergic and dopaminergic agents | ||
|---|---|---|
| C01CA24 | ||
| C01CA07 | ||
| C01CA04 | ||
| C01CA26 | ||
| C01CA02 | ||
| C01CA17 | ||
| C01CA24 | ||
| C01CA03 | ||
| C01CA06 | ||
| Phosphodiesterase inhibitors | ||
|---|---|---|
| C01CE02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Egan JR, et al., Levosimendan for low cardiac output: a pediatric experience, J Intensive Care Med, 2006, 2, 183-7
- Lechner E, et al., Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate, Pediatr Crit Care Med, 2007, 8, 61-3
- Namachivayam P, et al., Early experience with Levosimendan in children with ventricular dysfunction., Pediatr Crit Care Med, 2006, 7, 445-8
- Turanlahti M, et al., Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery., Pediatr Crit Care Med, 2004, 5, 457-62
- Angadi U, et al., Is levosimendan effective in paediatric heart failure and post-cardiac surgeris?, Interact Cardiovasc Thorac Surg, 2013, 17, 710-4
- Pellicer A, et al., Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery, 2013, 73, 95-103
- Fedele F, et al., Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms, Eur J Heart Fail, 2014, 16, 281-8
- Orion Pharma bvba, SmPC Simdax 11-6-2010, www.simdax.com
- CBG, Levosimendan containing products with a 2.5 mg/mL strength and the pharmaceutical form concentrate for solution for infusion for the proposed indication treatment of patients with acutely decompensated severe chronic heart failure (ADHF), www.cbg-meb.nl, 04-02-2016
- Amiet V. et al, Use of Levosimendan in Postoperative Setting After Surgical Repair of Congenital Heart Disease in Children., Pediatr Cardiol., 2018, Jan;39(1), 19-25
- Thorlacius EM, et al., Levosimendan Versus Milrinone for Inotropic Support in Pediatric Cardiac Surgery: Results From a Randomized Trial., J Cardiothorac Vasc Anesth, 2020, 34, 2072-80
- Lechner E, et al., Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate, Pediatr Crit Care Med, 2007, 8, 61-3
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
